Drug Trial Radar · NCT06384807
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Apr 22, 2024
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Conditions
- Solid Tumor
Interventions
BHV-1510Drug
BHV-1510 will be administered on Day 1 every 3 weeks
CemiplimabDrug
cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
BHV-1510Drug
BHV-1510 will be administered on Day 1 every 2 weeks
BHV-1510Drug
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
CemiplimabDrug
cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of patients with adverse events (AEs)Time frame: Through study completion, estimated as an average of 47 months
- Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)Time frame: Approximately 15 months
- Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months
- Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months
- Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Site-113
Duarte, California · Recruiting
Site-112
La Jolla, California · Recruiting
Site-111
Palo Alto, California · Recruiting
Site-114
Washington D.C., District of Columbia · Recruiting
Site-103
Miami, Florida · Recruiting
Site-105
Orlando, Florida · Recruiting
Site-115
Tampa, Florida · Recruiting
Site-110
Augusta, Georgia · Recruiting
Site-109
Detroit, Michigan · Recruiting
Site-101
St Louis, Missouri · Completed
Site-117
New York, New York · Recruiting
Site-116
Oklahoma City, Oklahoma · Recruiting
Site-108
Philadelphia, Pennsylvania · Recruiting
Site-107
Nashville, Tennessee · Recruiting
Site-104
Dallas, Texas · Recruiting
Site-106
West Valley City, Utah · Recruiting
Site-102
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.